OECD Blog Item Explores Why Biotech Start-Ups Lag in Europe

Why It Matters

Closing the biotech gap is critical for Europe to retain talent, attract private capital, and compete globally in high‑growth life‑science markets.

Key Takeaways

• EU biotech start‑ups lag in creation, patents, VC funding
• Biotech Act proposes regulatory sandboxes and fast‑track project designation
• €10 billion investment pilot aims to mobilize private capital
• Success hinges on agile regulation and financing reaching demo stage

Pulse Analysis

Europe’s biotech ecosystem has long been praised for its scientific excellence, yet the region consistently trails the United States and China in turning discoveries into thriving start‑ups. OECD data show lower rates of new biotech company formation, fewer patent applications, and a modest share of global venture‑capital dollars. This disparity hampers the EU’s ability to commercialize breakthroughs in gene therapy, synthetic biology, and personalized medicine, limiting both economic growth and strategic autonomy in a sector increasingly tied to national security.

In response, the European Commission’s Biotech Act, unveiled in December 2025, seeks to dismantle structural barriers. The legislation introduces regulatory sandboxes that let innovators test novel therapies under controlled conditions, while expanding pre‑submission consultations to streamline approval pathways. A strategic project designation promises fast‑track funding and regulatory clearance for high‑potential ventures. Complementing these measures, a €10 billion (approximately $10.8 billion) Health Biotechnology Investment Pilot, managed by the European Investment Bank, will employ risk‑sharing instruments to attract private investors to early‑stage companies. Together, these tools aim to create a more responsive, capital‑rich environment for biotech entrepreneurs.

The success of the Biotech Act will hinge on implementation. Agile regulation must translate into shorter timelines and lower compliance costs, especially during the costly demonstration and scale‑up phases where many start‑ups falter. Equally, the investment pilot must deliver tangible capital to firms that lack access to traditional financing. If these conditions are met, Europe could convert its research prowess into a robust pipeline of commercial biotech ventures, strengthening its position in the global life‑science market and delivering economic and health benefits to its citizens.